Granulocyte/Monocyte Apheresis (GMA) is a non-pharmacological therapeutic alternative for the treatment of Inflammatory Bowel Disease (IBD), among other immune-mediated diseases. GMA has proven to be very effective and safe. Furthermore, it remains the only therapy targeting neutrophils, which are the hallmark of inflammatory bowel disease and, specifically, of Ulcerative Colitis (UC).

GMA has proven its efficacy in different clinical scenarios, especially when administered early. Unlike pharmacological treatments, it is extremely safe and has a unique, very low, profile of adverse effects, which makes it the ideal treatment for certain patient profiles, such as children and frail patients. When combined with biological therapy, GMA is an ideal treatment to achieve full remissions without increasing the risk of serious adverse effects.

The need to improve the quality of life of patients with IBD (especially of those who cannot be treated with biological drugs), makes it necessary for professionals to update their knowledge about the advantages and benefits of alternatives to these treatments currently available, so that they can be offered to the right patients.